Setterwalls has assisted Recipharm AB (publ) in connection with an offer to acquire all shares in Consort Medical plc.
The enlarged Recipharm Group is set to become a top five global CDMO (Contract Development and Manufacturing Organisation), able to offer integrated device development and supply combined with commercial scale finished dose manufacturing. The shareholders in Consort Medical receives a consideration of GBP 10.10 per share, in cash, which represents an equity value of GBP 505 million (SEK 6,284 million) on a fully diluted basis. The offer is fully financed through bank facilities including a bridge facility of SEK 2,000 million. For further information about the acquisition and Recipharm, please refer to the company’s website: www.recipharm.com.